Posted by Michael Wonder on 18 Dec 2018
Eiger announces PRIME designation granted by European Medicines Agency for lonafarnib for treatment of hepatitis delta virus infection
18 December 2018 - Phase 3 hepatitis D virus “D-LIVR” international study initiating.
Eiger BioPharmaceuticals today announced the EMA has granted PRIME (PRIority MEdicines) designation for lonafarnib for the treatment of hepatitis delta virus (HDV) infection.
Eiger’s application was supported by data from Phase 2 clinical studies of lonafarnib treatment in HDV-infected patients, achieving endpoints which reflect an improvement in liver condition and virologic response rarely observed in untreated HDV patients. Lonafarnib is a first-in-class prenylation inhibitor for the treatment of HDV infection.
